BiomX has published promising phase 1b/2a trial results in Nature Communications, demonstrating that its phage cocktail BX004 significantly reduced bacterial levels in patients with cystic fibrosis (CF) and antibiotic-resistant Pseudomonas aeruginosa infections.
The study revealed a 2.7 log₁₀, or roughly 500-fold, greater bacterial reduction compared with placebo, marking a major advance for phage therapy in chronic respiratory conditions.
Importantly, the trial found no emergence of bacterial resistance to BX004 and showed preservation of the healthy microbiome, addressing key limitations of traditional antibiotics in this patient group.
The publication validates BiomX’s phage therapy platform, which uses engineered and natural bacteriophages to target disease-causing bacteria. BX004 was delivered via nebulisation during the study.
Jonathan Solomon, CEO of BiomX, said: “The publication of our peer-reviewed results in a preeminent research journal, including new data showing antimicrobial activity of BX004, provides significant third-party validation of our phage therapy platform to treat patients with chronic P. aeruginosa cystic fibrosis infections.”
BiomX has already initiated a phase 2b trial of BX004, with topline results expected in the first quarter of 2026.
Rotem Sorek, Professor of Genetics at the Weizmann Institute of Science, said: “By combining experimental and computational methods, we’ve developed a design approach that broadens bacterial strain coverage, lowers the likelihood of resistance, and enhances activity against bacterial biofilms, establishing an effective framework for designing next-generation bacteriophage therapeutics.”
The peer-reviewed data, drawn from the first human trial of BX004, adds momentum to the use of phage therapy in treating antibiotic-resistant infections where treatment options are limited.
